A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial

Trial Profile

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Brexpiprazole (Primary) ; Antidepressants
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Acronyms Orion
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 22 Jun 2017 This trial has been completed in Germany (End date:2017-05-18).
    • 25 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
    • 25 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top